Oncotype and EndoPredict News

This is selected news for Oncotype and EndoPredict, which are both filed under Sectors / Healthtech. There are 9 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/6/2020 Potential Factors in Prognostic Discrepancies Among Tests for Recurrence Risk in Patients With Breast Cancer Receiving Endocrine Therapy
... for determining the risk of breast cancer recurrence in patients with estrogen receptor‚Aipositive, HER2-negative disease receiving endocrine therapy. The investigators found that the Oncotype DX recurrence score (RS) is dominated by information on estrogen signaling, whereas the Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR ...
ascopost.com
10/30/2020 Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test's Genomic Underpinning Drives Prognostic Performance | Business & Finance | heraldchronicle.com
... compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI). It expands upon a previous evaluation of these same tests using an identical dataset, which compared their ability ...
Business Wire
10/30/2020 Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test's Genomic Underpinning Drives Prognostic Performance
... breast cancer tests. The study compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI). It expands upon a previous evaluation of these same tests using an identical ...
BioSpace
6/26/2020 Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients
... in the (neo-)adjuvant setting of breast cancer therapy was improved due to the implementation of multi gene expression tests such as Oncotype DX and EndoPredict tests in selective patients' cohorts. Spite of these advances in molecular analysis of primary tumor genotypes, in the setting of advanced disease, molecular genetic ...
12/3/2019 Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
... with pathogenic variants in the ataxia telangiectasia mutated (ATM) gene Michael Hall Poster (P5-03-02) Friday, Dec. 13 5:00-7:00 p.m. EndoPredict ® Prognostic value of EndoPredict and Oncotype Recurrence Score according to patients' age Ivana Sestak Poster (P5-06-04) Friday, Dec. 13 5:00-7:00 p.m. Correlation between and molecular drivers of Oncotype DX, Prosigna ...
BioSpace
6/25/2019 Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer Nasdaq:MYGN
Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ June 25, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the ...
Globe Newswire
6/25/2019 Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
... of the EndoPredict ® test compared to other breast cancer assays. The key finding is that EndoPredict test was more than twice as cost effective as Oncotype DX®. Breast cancer is the most common cancer in women worldwide. “Payers would benefit from understanding the financial implications of using gene expression tests ...
Business Insider
6/25/2019 ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer
... node-positive disease ( evidence based, intermediate, moderate ). It should not be used in patients with HER2-positive or triple-negative disease (informal consensus, insufficient, strong ). EndoPredict If a patient has estrogen receptor/progesterone receptor-positive, HER2-negative, node-negative breast cancer, the EndoPredict 12-gene recurrence score may be used ...
ascopost.com